naoto.matsuda

August 9, 2024 EVerMed Inc. has raised 280 million yen in the 1st close of its seed round EVerMed Inc. has raised a total of 280 million yen through a third-party allotment of new shares to WUV 1 Limited Partnership (Shinjuku-ku, Tokyo; operating company: Waseda University Ventures, Inc.; CEO: Tetsuya Read more…

August 2, 2024 Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells EVerMed Inc. and KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Yutaka Ogihara, hereafter “KYORIN”) today announced that they have entered into an option agreement for drug discovery of extracellular vesicles Read more…